Lv4
476 积分 2022-06-28 加入
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
3天前
已完结
Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin
3天前
已完结
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
4天前
已完结
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
4天前
已完结
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
4天前
已完结
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers
4天前
已完结
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
6天前
已完结
Improving outcomes of patients with pancreatic cancer
6天前
已完结
Loss of Major Histocompatibility Complex Class I, CD8+ Tumor-infiltrating Lymphocytes, and PD-L1 Expression in Ovarian Clear Cell Carcinoma
19天前
已完结
Single-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomes
22天前
已完结
皖公网安备34019202002308
